Healthcare Industry News: HSMN NewsFeed

Devices Orthopaedic

 News Release - June 3, 2020

New publication shows Smith & Nephew's OXINIUM(TM) (Oxidized Zirconium) on XLPE for total hip arthroplasty as best performing bearing beyond 10 years

LONDON, June 3, 2020 -- (Healthcare Sales & Marketing Network) -- Smith & Nephew (LSE: SN,NYSE: SNN), the global medical technology business, today announced the publication of new clinical evidence further validating the exceptional performance of its proprietary OXINIUM - Oxidized Zirconium - on XLPE (highly cross-linked polyethylene) for total hip arthroplasty (THA). The publication in The Journal of Bone and Joint Surgery Open Access analyses data from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man (NJR) and concludes that THA procedures using OXINIUM on XLPE were associated with the lowest risk of revision of all bearing combinations for any reason beyond 10 years.1

This analysis of more than 400,000 THAs* confirms that procedures using OXINIUM on XLPE showed:
  • 1.96% cumulative incidence of revision at 10 years1 compared with the average of 4.79% for primary hip replacements.2
  • 48% reduction in risk for aseptic loosening compared to metal on XLPE.1
  • Lowest revision risk vs. all bearing combinations in patients less than 55 years old.1
  • Lower risk of revision compared to ceramic-on-ceramic hip bearing combinations.1
(*based on UK NJR data analysis of cementless and hybrid THA data.1)

"Total hip arthroplasty using a bearing combination of OXINIUM on XLPE versus traditional ceramic or metal constructs results in greatly improved survivorship and significantly reduced the need for revision," said Prof. Edward T. Davis FRCS, of The Royal Orthopaedic Hospital NHS Foundation Trust. "Even in the younger more active patients, the results are spectacular, and I am excited to continue using OXINIUM on XLPE to deliver better outcomes for my patients."

The new analysis of NJR data corroborates a similar report from the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR), and publications referencing the Italian Registry (RIPO; Register of Orthopaedic Prosthetic Implants) and the Dutch Arthroplasty Register (LROI), which all confirm the positive effect that modern bearing surface combinations like OXINIUM on XLPE have on THA survival.3,4,5

"Registries throughout the world have highlighted the performance of OXINIUM for total hip arthroplasty. This publication is further evidence of the success of our truly differentiated and proven technology," said Skip Kiil, President of Global Orthopaedics at Smith & Nephew. "THA is considered one of the most clinically successful procedures in modern medicine, and OXINIUM on XLPE continues to raise the bar for acceptable revision rates."

To learn more about OXINIUM on XLPE and VERILAST™ Technology for hips, please visit http://rediscoveryourgo.com/verilasthip.aspx

References
  1. Davis ET, Pagkalos J, Kopjar B. Effect of Bearing Surface on Survival of Cementless and Hybrid Total Hip Arthroplasty. JBJS Open Access. 2020;5(2): e0075. doi:10.2106/jbjs.oa.19.00075
  2. National Joint Registry for England, Wales, Northern Ireland and the Isle of Man: 16th Annual Report 2019. Available at: https://reports.njrcentre.org.uk. Accessed 5 February 2019.
  3. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) Hip, Knee & Shoulder Arthroplasty: 2019 Annual Report. Available at: https://aoanjrr.sahmri.com/annual-reports-2019. Accessed 22 November 2019.
  4. Atrey A, Ancarani C, Fitch D, Bordini B. Impact of bearing couple on long-term component survivorship for primary cementless total hip replacement in a large arthroplasty registry. Poster presented at: Canadian Orthopedic Association; June 20–23, 2018; Victoria, British Columbia, Canada.
  5. Peters RM, Van Steenbergen LN, Stevens M, Rijk PC, Bulstra SK, Zijlstra WP. The effect of bearing type on the outcome of total hip arthroplasty. Acta Orthop. 2018;89(2):163–169. doi:10.1080/17453674.2017.1405669
About Smith & Nephew

Smith & Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,500+ employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. Smith & Nephew is a constituent of the FTSE100 (LSE: SN,NYSE: SNN). The terms 'Group' and 'Smith & Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith & Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

™ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.


Source: Smith & Nephew

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.